Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Partnering / Licensing

Bioscience Valuation supports senior management in Partnering (e.g., in- and outlicensing) efforts:
  • full evaluation of the asset, including all commercial, R&D and financial attributes,
  • creation of long and short lists of potential partners,
  • initiating contact and communication between client and target company,
  • drafting term sheets,
  • supporting the negotiations until an agreement has been signed,
  • monitoring partnership progress and ensuring satisfaction of all parties after the deal.


Case:
A leading Southern-European company was searching for in-licensing opportunities. Bioscience Valuation (BSV) screened the worldwide pharmaceutical markets in a comprehensive and systematic way.

Bioscience Valuation identified promising drugs that were EMA-approved and ready to get marketed; BSV drafted the term sheet and supported the negotiations. Bioscience Valuation's client licensed the drug that is now distributed in the local market.